TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23998674

Group type: EXPERIMENTAL
Intervention: Increased functional connectivity between the dorsomedial prefrontal cortex (DMPFC) and the right posterior superior temporal sulcus (pSTS) during social emotion processing compared to basic emotion processing.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased functional connectivity between the DMPFC and the right TPJ during social emotion processing, associated with increasing oestradiol concentrations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced functional connectivity between the DMPFC and the left anterior temporal cortex (ATC) during social emotion processing, associated with more advanced puberty stage.
Number of subjects: 0
Study: 21572124

Group type: EXPERIMENTAL
Intervention: sialyl-TN (STn) keyhole limpet hemocyanin (KLH) vaccine
Number of subjects: 1028

Group type: COMPARATOR
Intervention: 100 μg KLH plus adjuvant (control group)
Number of subjects: 1028
Study: 19173846

Group type: EXPERIMENTAL
Intervention: Community-based hypertension self-management program
Number of subjects: 373

Group type: COMPARATOR
Intervention: Routine hypertension management services (Control)
Number of subjects: 373
Study: 16508317

Group type: EXPERIMENTAL
Intervention: PPI + eradication (group 2)
Number of subjects: 61

Group type: COMPARATOR
Intervention: PPI‐only (group 1)
Number of subjects: 61
Study: 12699477

Group type: EXPERIMENTAL
Intervention: Electronic diary
Number of subjects: 35

Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 35
Study: 10974959

Group type: EXPERIMENTAL
Intervention: Intensive case management (case-loads 10-15)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Standard case management (case-loads 30-35)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 708

Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 708
Study: 9006235

Group type: EXPERIMENTAL
Intervention: THR education booklet received in the mail 4-6 weeks before surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Booklet (control group)
Number of subjects: 0
Study: 1616214

Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg, twice daily for 5 days
Number of subjects: 511

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study: 6232402

Group type: EXPERIMENTAL
Intervention: 10-micrograms dose of HBsAg vaccine administered at 0, 1, and 6 months
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 10-micrograms dose of HBsAg vaccine
Number of subjects: 37
Study: 3723285

Group type: EXPERIMENTAL
Intervention: Film 'Touch' (Illusion Theater Co. & Media Ventures, Inc., 1984)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no film)
Number of subjects: 67
Study: 29455305

Group type: EXPERIMENTAL
Intervention: Active LASER (904 nm, 60 mW, 250 Hz, 3.6 J per diode, total dose of 129.6 J)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Active LASER (904 nm)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 27578220

Group type: EXPERIMENTAL
Intervention: Adjunctive metformin therapy (in addition to insulin)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Insulin alone (control group)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Adjunctive metformin therapy
Number of subjects: 84
Study: 23824087

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment program
Number of subjects: 937

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 937
Study: 23939415

Group type: EXPERIMENTAL
Intervention: Nonlinear mixed effects modeling of diurnal systolic blood pressure (SBP)
Number of subjects: 196
Study: 19484712

Group type: EXPERIMENTAL
Intervention: Internet peer support condition
Number of subjects: 78

Group type: COMPARATOR
Intervention: Internet-based educational control condition
Number of subjects: 78
Study: 18257143

Group type: EXPERIMENTAL
Intervention: Moderate to severe rectocele
Number of subjects: 11096

Group type: EXPERIMENTAL
Intervention: Moderate to severe prolapse
Number of subjects: 11096
Study: 16637746

Group type: EXPERIMENTAL
Intervention: Fearful faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioned neutral faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral faces
Number of subjects: 0
Study: 12909597

Group type: EXPERIMENTAL
Intervention: Bed rest for 6 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-bed rest period
Number of subjects: 8
Study: 10790249

Group type: EXPERIMENTAL
Intervention: Treatment music tape (TT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Familiar music tape (FT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No audiotape (NT)
Number of subjects: 0
Study: 8864317

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5 mg single oral dose after stopping SASP for 2 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5 mg weekly + 2000 mg SASP daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clinical measurements (Ritchie articular index, number of swollen joints, ESR, disease activity score)
Number of subjects: 15
Study: 1633285

Group type: EXPERIMENTAL
Intervention: Treadmill movement with optical flow pattern (0.25 Hz)
Number of subjects: 0
Study: 6094442

Group type: EXPERIMENTAL
Intervention: Cefotaxime and metronidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clindamycin and tobramycin
Number of subjects: 0
Study: 30274758

Group type: EXPERIMENTAL
Intervention: FA training only
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: FA + HC training
Number of subjects: 317

Group type: COMPARATOR
Intervention: No prior training
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Prior FA + HC training
Number of subjects: 317
Study: 30243296

Group type: EXPERIMENTAL
Intervention: Unloader One® Knee Brace
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control placebo group (look-alike brace with active strips removed)
Number of subjects: 149
Study: 26600556

Group type: EXPERIMENTAL
Intervention: Computerised training
Number of subjects: 55

Group type: COMPARATOR
Intervention: Attention-control condition
Number of subjects: 55
Study: 24853922

Group type: EXPERIMENTAL
Intervention: Electrodiagnostic testing
Number of subjects: 38
Study: 22575499

Group type: EXPERIMENTAL
Intervention: PALs intervention
Number of subjects: 100
Study: 20087340

Group type: EXPERIMENTAL
Intervention: Drugs (888 drugs connected to side effects)
Number of subjects: 888

Group type: COMPARATOR
Intervention: Placebo administration (199 drugs)
Number of subjects: 888
Study: 18593998

Group type: EXPERIMENTAL
Intervention: BMS-275183 administered under fasting conditions (A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: BMS-275183 administered after a low-fat meal (B)
Number of subjects: 31

Group type: COMPARATOR
Intervention: BMS-275183 administered after a high-fat meal (C)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: BMS-275183 administered with BSA-normalized dosing (D)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: BMS-275183 overall
Number of subjects: 31
Study: 15653291

Group type: EXPERIMENTAL
Intervention: Task-cueing conditions (informative pre-cues)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No task-cueing conditions (uninformative pre-cues)
Number of subjects: 0
Study: 12521503

Group type: EXPERIMENTAL
Intervention: Propess (slow release prostaglandin pessary)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Prostin gel (instant release prostaglandin gel)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Propess
Number of subjects: 95
Study: 9673744

Group type: EXPERIMENTAL
Intervention: Nebulised terbutaline (cumulative dose 10 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nebulised saline
Number of subjects: 18
Study: 8022954

Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
Number of subjects: 204
Study: 2562913

Group type: EXPERIMENTAL
Intervention: Activated charcoal alone
Number of subjects: 200

Group type: COMPARATOR
Intervention: Syrup of ipecac and activated charcoal
Number of subjects: 200
Study: 792737

Group type: EXPERIMENTAL
Intervention: parsalmide
Number of subjects: 40

Group type: COMPARATOR
Intervention: phenybutazone
Number of subjects: 40
Study: 30861998

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care + conventional physical therapy
Number of subjects: 20
Study: 30106636

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab and an aromatase inhibitor (AI)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Trastuzumab and an AI
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab
Number of subjects: 129

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 129
Study: 27401244

Group type: EXPERIMENTAL
Intervention: Tivozanib plus mFOLFOX6 (1.5 mg orally once daily for 21 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bevacizumab plus mFOLFOX6 (5 mg/kg intravenously every 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tivozanib plus mFOLFOX6
Number of subjects: 0
Study: 23909813

Group type: EXPERIMENTAL
Intervention: Sorbitol (10 g)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mannitol (10 g)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Glucose (10 g)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both polyols (sorbitol and mannitol)
Number of subjects: 41
Study: 21252373

Group type: EXPERIMENTAL
Intervention: Students with LD using assistive technology and web courses
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Students with LD
Number of subjects: 964

Group type: COMPARATOR
Intervention: Comparison group (students without LD)
Number of subjects: 964
Study: 19579757

Group type: EXPERIMENTAL
Intervention: Liberal PRBC transfusion criteria (n=17)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Restrictive PRBC transfusion criteria (n=19)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Total transfused blood volume greater than 30 mL over 30 days
Number of subjects: 36
Study: 17210036

Group type: EXPERIMENTAL
Intervention: Adenosine A(2A) receptor agonist/adenosine A(3) receptor antagonist (50 micro g), administered twice daily for 7 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intranasal fluticasone proprionate nasal spray (FPANS), administered twice daily for 7 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15177710

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 12
Study: 11585150

Group type: EXPERIMENTAL
Intervention: Training with air
Number of subjects: 20

Group type: COMPARATOR
Intervention: Training with oxygen
Number of subjects: 20
Study: 9413755

Group type: EXPERIMENTAL
Intervention: No antibiotic prophylaxis (sterile urine group)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (urinary tract infection group)
Number of subjects: 340
Study: 8004733

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study: 3316565

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ceftazidime and Placebo
Number of subjects: 16
Study: 31489650

Group type: EXPERIMENTAL
Intervention: 1200 mg PTX in 3 divided doses plus 25 mg captopril 3 times a day
Number of subjects: 62

Group type: COMPARATOR
Intervention: 75 mg captopril in 3 divided doses
Number of subjects: 62
Study: 30359047

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) system for daily monitoring of illicit opioid use
Number of subjects: 24

Group type: COMPARATOR
Intervention: Timeline Follow-Back (TLFB) interviews
Number of subjects: 24
Study: 28723843

Group type: EXPERIMENTAL
Intervention: High carbohydrate (CHO) manipulation (414 ± 2.4 g)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Low carbohydrate (CHO) manipulation (79.5 ± 1.0 g)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (High and Low CHO)
Number of subjects: 26
Study: 25355640

Group type: EXPERIMENTAL
Intervention: T/T genotype of XRCC2 -41657C/T polymorphism
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: T allele of XRCC2 polymorphism
Number of subjects: 1008

Group type: COMPARATOR
Intervention: XRCC2 -41657C/T genotypes in subgroups assigned to histological grades
Number of subjects: 1008
Study: 23283805

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 610

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 610
Study: 20492049

Group type: EXPERIMENTAL
Intervention: Listening to specially selected, relaxing music at home for at least 30 minutes a day over two weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Regular postpartum care only
Number of subjects: 77
Study: 19019818

Group type: EXPERIMENTAL
Intervention: Alive! intervention group
Number of subjects: 787
Study: 17030754

Group type: EXPERIMENTAL
Intervention: Higher BMI (quintiles of BMI at baseline)
Number of subjects: 2223

Group type: EXPERIMENTAL
Intervention: Higher BMI at baseline
Number of subjects: 2223

Group type: EXPERIMENTAL
Intervention: Changes in BMI
Number of subjects: 2223
Study: 12879828

Group type: EXPERIMENTAL
Intervention: Prioritized review criteria for asthma and angina
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Prioritized review criteria plus feedback for asthma and angina
Number of subjects: 81

Group type: COMPARATOR
Intervention: Full guidelines for asthma and angina
Number of subjects: 81
Study: 11291296

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 50
Study: 8973991

Group type: EXPERIMENTAL
Intervention: High-protein food
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no high-protein food)
Number of subjects: 12
Study: 8198418

Group type: EXPERIMENTAL
Intervention: Salbutamol (400 micrograms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (72 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (four puffs)
Number of subjects: 10
Study: 2443727

Group type: EXPERIMENTAL
Intervention: Bladder neck resection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate
Number of subjects: 30
Study: 29239242

Group type: EXPERIMENTAL
Intervention: Fluconazole-loaded solid lipid nanoparticles (FLZ-SLNs) topical gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Candistan® 1% cream (control)
Number of subjects: 30
Study: 27548351

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab treatment
Number of subjects: 325
Study: 24259750

Group type: EXPERIMENTAL
Intervention: Gastrocnemius stretching in pronation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Gastrocnemius stretching in supination
Number of subjects: 27
Study: 22784254

Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) treatment in Graves' disease patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Propylthiouracil (PTU) treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MMI treatment
Number of subjects: 28
Study: 20653820

Group type: EXPERIMENTAL
Intervention: GTR combined with DBBM hydrated in saline (DBBM-)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GTR combined with DBBM hydrated in gentamicin sulphate (DBBM+)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GTR alone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no grafting)
Number of subjects: 45
Study: 17592313

Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine 0.4% (Acular LS)
Number of subjects: 7

Group type: COMPARATOR
Intervention: nepafenac sodium 0.1% (Nevanac)
Number of subjects: 7
Study: 15860498

Group type: EXPERIMENTAL
Intervention: Circular excision and subsequent stripping
Number of subjects: 48

Group type: COMPARATOR
Intervention: Immediate stripping
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Stripping
Number of subjects: 48

Group type: COMPARATOR
Intervention: Coagulation and cutting
Number of subjects: 48
Study: 12138270

Group type: EXPERIMENTAL
Intervention: High-flux polysulfone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-flux polysulfone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cuprophan
Number of subjects: 0
Study: 9734730

Group type: EXPERIMENTAL
Intervention: Long-term dietary olive oil intervention (MUFA diet)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (SFA-enriched diet)
Number of subjects: 23
Study: 8091152

Group type: EXPERIMENTAL
Intervention: School-based health counselling programme
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 118
Study: 3041937

Group type: EXPERIMENTAL
Intervention: Tolazamide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31609882

Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA (DAXI) 40 U
Number of subjects: 609
Study: 29363329

Group type: EXPERIMENTAL
Intervention: Postural control intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 26586266

Group type: EXPERIMENTAL
Intervention: Professional interventions aimed at diminishing neuropsychiatric symptoms in dementia patients and improving caregiver's sense of competence.
Number of subjects: 0
Study: 26332473

Group type: EXPERIMENTAL
Intervention: Educational intervention (E) - focused didactic lecture and periodic e‐mail reminders with immediate feedback
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 244
Study: 23782622

Group type: EXPERIMENTAL
Intervention: DSMS delivered by educator
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: DSMS delivered by peer
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: DSMS delivered by practice staff
Number of subjects: 141

Group type: COMPARATOR
Intervention: Usual education (control)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: All DSMS groups
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 141
Study: 21346095

Group type: EXPERIMENTAL
Intervention: Total Testosterone (TT)
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Free Testosterone (FT)
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Total Estradiol (E(2))
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Free Estradiol (E(2))
Number of subjects: 1489
Study: 18501066

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letrozole plus Lapatinib
Number of subjects: 0
Study: 17575805

Group type: EXPERIMENTAL
Intervention: Highly purified omega-3 polyunsaturated fatty acids (PUFAs) at a dose of 1 g/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard secondary pharmacological prevention therapy (anti-platelet agents, statins, beta-blockers, ACE inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highly purified omega-3 PUFAs
Number of subjects: 0
Study: 14530016

Group type: EXPERIMENTAL
Intervention: Intermittent antegrade cold blood cardioplegia
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intermittent retrograde cold blood cardioplegia
Number of subjects: 39
Study: 10894877

Group type: EXPERIMENTAL
Intervention: Daniplestim (2.5 microgram/kg/d) plus G-CSF (10 microgram/kg/d)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo plus G-CSF (10 microgram/kg/d)
Number of subjects: 52
Study: 8931033

Group type: EXPERIMENTAL
Intervention: Calcium citrate solution (500 mg Ca2+)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Calcium lactogluconate/carbonate solution (500 mg Ca2+)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Calcium citrate suspension (500 mg Ca2+)
Number of subjects: 18
Study: 1486427

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control group (not selected according to ER status)
Number of subjects: 0
Study: 3917619

Group type: EXPERIMENTAL
Intervention: Active surveillance (weekly telephone contact)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Passive surveillance (no contact)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 216
Study: 31485014

Group type: EXPERIMENTAL
Intervention: Goat lung surfactant extract (GLSE)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Bovine surfactant extract (beractant; Survanta®)
Number of subjects: 98
Study: 30077574

Group type: EXPERIMENTAL
Intervention: Resistance + aerobic training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo control group (stretching)
Number of subjects: 36
Study: 27776675

Group type: EXPERIMENTAL
Intervention: Problem Recognition Questionnaire (PRQ) pre-treatment
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Problem Recognition Questionnaire (PRQ) post-treatment
Number of subjects: 191
Study: 24556276

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (beer and spirits)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total alcohol volume and drinking in public settings
Number of subjects: 0
Study: 22250855

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (monitored Internet discussion forum)
Number of subjects: 99
Study: 20054046

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol
Number of subjects: 849

Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 849
Study: 17913408

Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract (250 mg of standardized soy extract, total of 100 mg/day of isoflavone)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract
Number of subjects: 80
Study: 15643102

Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine capsules administered rectally
Number of subjects: 7

Group type: COMPARATOR
Intervention: 20 mg fluoxetine capsules administered orally
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Rectal route of administration
Number of subjects: 7